Page last updated: 2024-11-13

peptide yy

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

peptide YY (3-36): amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126455957
MeSH IDM0029538
PubMed CID90479816
MeSH IDM0029538

Synonyms (19)

Synonym
PYY ,
peptide yy
unii-t2670c12i5
J-004037
peptide yy, human
118997-30-1
peptide yy (human)
tyr-pro-ile-lys-pro-glu-ala-pro-gly-glu-asp-ala-ser-pro-glu-glu-leu-asn-arg-tyr-tyr-ala-ser-leu-arg-his-tyr-leu-asn-leu-val-thr-arg-gln-arg-tyr-nh2
peptide yy (1-36)
peptide yy [mi]
peptide yy human
T2670C12I5 ,
pyy (1-36) peptide
pyy(1-36)
peptide yy (3-36)
126339-09-1
AKOS024456705
AS-82377
PD079098

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The most common adverse events (AEs) were nausea, vomiting or administration site reactions, which were mild in most cases and settled with time."( Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial.
Ball, LJ; Bloom, SR; Brindley, C; Bush, J; Day, E; Fiorentino, F; Khoo, B; Malviya, R; Minnion, J; Tan, TM, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The terminal elimination half-life was ~13 h when administered as an oral suspension formulation."( Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects.
Gambale, JJ; Katz, LB; Polidori, DC; Rothenberg, PL; Sarich, TC; Stein, PP; Vaccaro, N; Vanapalli, SR; Vets, E; Xi, L, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
"New approaches for enhancing intranasal drug delivery based on recent discoveries on the molecular biology of tight junctions (TJ) are significantly improving the bioavailability of 'non-Lipinsky' small molecules, and peptide, protein and oligonucleotide drugs."( Advances in nasal drug delivery through tight junction technology.
Johnson, PH; Quay, SC, 2005
)
0.33
" All three meals contained [(13)C]glucose (3 mg/kg body wt) to assess the bioavailability of ingested glucose."( Reducing dietary fat from a meal increases the bioavailability of exogenous carbohydrate without altering plasma glucose concentration.
Horowitz, JF; Knuth, ND; Shrivastava, CR, 2009
)
0.35
" In addition, photocrosslinked poly(ester anhydride)s increased the bioavailability of PYY3-36 by up to 20-fold in comparison with subcutaneous administration of solution, evidence of remarkably improved delivery."( Photocrosslinked poly(ester anhydride)s for peptide delivery: Effect of oligomer hydrophobicity on PYY3-36 delivery.
Hakala, RA; Herzig, KH; Järvinen, K; Korhonen, H; Kovalainen, M; Mönkäre, J; Seppälä, JV, 2012
)
0.38
" The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release."( Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.
Herzig, KH; Järvinen, K; Kovalainen, M; Lehto, VP; Mäkilä, E; Mönkäre, J; Salonen, J, 2012
)
0.38
" Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36."( Development of porous silicon nanocarriers for parenteral peptide delivery.
Herzig, KH; Järvinen, K; Kaasalainen, M; Kovalainen, M; Lehto, VP; Mönkäre, J; Riikonen, J; Salonen, J, 2013
)
0.39
" bioavailability yet retaining its potency."( Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.
Alvarez Sanchez, R; Beauchamp, J; Conde-Knape, K; Dehmlow, H; Iglesias, A; Mattei, P; Raab, S; Sewing, S; Sprecher, U; Ullmer, C, 2013
)
0.39
" In contrast to the orally bioavailable agonist RO5527239, we show that tauro-RO5527239 triggers PYY release only when applied intravenously."( Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.
Alvarez Sanchez, R; Beauchamp, J; Conde-Knape, K; Dehmlow, H; Iglesias, A; Mattei, P; Raab, S; Sewing, S; Sprecher, U; Ullmer, C, 2013
)
0.39
" Study 1 compared the bioavailability and effects on circulating glucose and gut hormones (glucagon-like peptide-1, peptide YY) of Metformin DR dosed twice-daily to twice-daily immediate-release metformin (Metformin IR)."( Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
Baron, A; Burns, C; Buse, JB; DeFronzo, RA; Fineman, M; Kim, T; Skare, S, 2016
)
0.43
" In the evaluable population, Metformin DR administered once-daily in the morning had 28% (90% CI -16%, -39%) lower bioavailability (least squares mean ratio of metformin AUC0-24) compared with either once-daily in the evening or twice-daily, although the glucose-lowering effects were maintained."( Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
Baron, A; Burns, C; Buse, JB; DeFronzo, RA; Fineman, M; Kim, T; Skare, S, 2016
)
0.43
"New approaches for enhancing intranasal drug delivery based on recent discoveries on the molecular biology of tight junctions (TJ) are significantly improving the bioavailability of 'non-Lipinsky' small molecules, and peptide, protein and oligonucleotide drugs."( Advances in nasal drug delivery through tight junction technology.
Johnson, PH; Quay, SC, 2005
)
0.33
" All three meals contained [(13)C]glucose (3 mg/kg body wt) to assess the bioavailability of ingested glucose."( Reducing dietary fat from a meal increases the bioavailability of exogenous carbohydrate without altering plasma glucose concentration.
Horowitz, JF; Knuth, ND; Shrivastava, CR, 2009
)
0.35
" In addition, photocrosslinked poly(ester anhydride)s increased the bioavailability of PYY3-36 by up to 20-fold in comparison with subcutaneous administration of solution, evidence of remarkably improved delivery."( Photocrosslinked poly(ester anhydride)s for peptide delivery: Effect of oligomer hydrophobicity on PYY3-36 delivery.
Hakala, RA; Herzig, KH; Järvinen, K; Korhonen, H; Kovalainen, M; Mönkäre, J; Seppälä, JV, 2012
)
0.38
" Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36."( Development of porous silicon nanocarriers for parenteral peptide delivery.
Herzig, KH; Järvinen, K; Kaasalainen, M; Kovalainen, M; Lehto, VP; Mönkäre, J; Riikonen, J; Salonen, J, 2013
)
0.39

Dosage Studied

Peptide YY3-36 has shown efficacy in appetite suppression when dosed by injection modalities (intraperitoneal (IP)/subcutaneous)

Peptide YY3-36 has shown efficacy in appetite suppression when dosed by injection modalities (intraperitoneal (IP)/subcutaneous) While emesis induced by intraperitoneally dosed to DON in the mink has been related to plasma up-grading of 5-hydroxytryptamine (5-HT)

ExcerptRelevanceReference
" The greatest effect was seen after the highest dosage tested."( Neuropeptide Y 16-36 inhibits mucociliary activity but does not affect blood flow in the rabbit maxillary sinus in vivo.
Cervin, A, 1992
)
0.28
" Porcine and human NPY and porcine PYY gave similar dose-response curves."( Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line.
Fishman, PH; Gordon, EA; Kohout, TA, 1990
)
0.28
" NPY injection increased significantly IR-ANF while PYY decreased IR-ANF in the dose-response manner in normally-hydrated rats as well as in water-loaded rats."( Opposite effects of neuropeptide Y (NPY) and polypeptide YY (PYY) on plasma immunoreactive atrial natriuretic factor (IR-ANF) in rats.
Baranowska, B; Cantin, M; Genest, J; Gutkowska, J; Lemire, A, 1987
)
0.27
" A dose-response curve was obtained, with the 10 ng/kg/min dose producing serum levels of 725 pg/ml."( Peptide YY inhibits cholecystokinin-stimulated sphincter of Oddi activity in the prairie dog.
Couse, NF; Grace, PA; Pitt, HA; Taylor, IL, 1988
)
0.27
" Increasing concentrations (10(-9)-10(-6) M) of the Y1 receptor antagonist, BIBP 3226, to human cerebral vessels caused a parallel and rightward shift in the NPY dose-response curves without any significant change in the maximal contractile response."( Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.
Abounader, R; Hamel, E; Villemure, JG, 1995
)
0.29
" The dose-response curves obtained with neuropeptide Y, peptide YY and with C-terminal fragments such as neuropeptide Y-(2-26), neuropeptide Y-(13-36) and peptide YY-(3-36) have similar slopes and maxima."( The dog saphenous vein: a sensitive and selective preparation for the Y2 receptor of neuropeptide Y.
Dumont, Y; Fournier, A; Pheng, LH; Quirion, R; Regoli, D, 1997
)
0.3
" Furthermore, 5 microM BIBP-3226, a Y1-receptor antagonist, shifted both dose-response curves to the right in a similar fashion for both peptides."( Human syncytiotrophoblast NPY receptors are located on BBM and activate PLC-to-PKC axis.
Ech-Chadli, H; Lafond, J; Robidoux, J; Simoneau, L; St-Pierre, S, 1998
)
0.3
" [Leu31 Pro34]-rNPY (agonist potency: Y1 > Y5 > Y4 = y6) and human pancreatic polypeptide (hPP) produced flatter dose-response curves, suggesting partial agonism at the receptor(s)."( Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?
Arch, JR; Buckingham, RE; Haynes, AC; McClue, S; Wilson, S, 1998
)
0.3
" We performed a dose-response study [ingestion of increasing amounts of glucose and complex carbohydrates (boiled rice and wheat bread), and the nonabsorbable disaccharide lactulose] in SB patients with an intact colon."( Importance of colonic bacterial fermentation in short bowel patients: small intestinal malabsorption of easily digestible carbohydrate.
Gudmand-Høyer, E; Holst, JJ; Jørgensen, S; Olesen, M, 1999
)
0.3
" At the 120-min time point, PYY was 2- to 10-times as potent as NPY over the dose-response range and stimulated twice the total intake at the maximally effective dose (2-fold greater efficacy)."( Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats.
Conze, DB; Corp, ES; Krasnicki, S; McQuade, J, 2001
)
0.31
" At Day 18 of incubation, treated eggs were injected into the air cell with 100 microl of either PYY (Trial 1) or EGF (Trial 2) at a dosage of 600 microg/kg egg weight."( In ovo peptide YY and epidermal growth factor administration and their effects on growth and yolk utilization in neonatal meat-type chickens (Gallus domesticus).
Croom, J; Daniel, LR; Maslin, WR; Peebles, ED; Taylor, IL; Whitmarsh, SK, 2001
)
0.31
" Thus dosage pattern is critical for producing a sustained effect of PYY(3-36) on food intake and adiposity."( Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats.
Chelikani, PK; Haver, AC; Keire, DA; Reeve, JR; Reidelberger, RD, 2006
)
0.33
" In addition, a formulation containing PYY(3-36) and TJM peptide was dosed intranasally in rabbits, resulting in a dramatic increase in bioavailability."( Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.
Chen, SC; Costantino, HR; Cui, K; Eiting, K; Farber, K; Houston, ME; Johnson, PH; Leonard, AK; Li, CY; Morris, D; Quay, SC; Sileno, AP, 2006
)
0.33
" Anorexia has also been confirmed in human studies although optimal route and dosing remain to be defined."( Recent progress in PYY research--an update report for 8th NPY meeting.
Ashby, D; Bloom, SR, 2007
)
0.34
" This dosing strategy produced a sustained reduction in daily caloric intake of 11-32% and prevented body weight gain (8 +/- 6 vs."( Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.
Chelikani, PK; Haver, AC; Reidelberger, RD, 2007
)
0.34
" Dose-response curves were constructed for each candidate messenger that significantly (p<0."( Secretion of ghrelin from rat stomach ghrelin cells in response to local microinfusion of candidate messenger compounds: a microdialysis study.
de la Cour, CD; Håkanson, R; Norlén, P, 2007
)
0.34
" A dose-dependent reduction in body weight in diet-induced obese (DIO) mice is seen following daily dosing for 14 days."( A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.
Buckholz, TM; Claus, TH; DeCarr, LB; Livingston, JN; Lumb, KJ; Mahle, CD; Mays, MR; Milardo, LF; Ortiz, AA, 2007
)
0.34
" Our aim here was to identify an intermittent dosing strategy for intraperitoneal infusion of peptide YY(3-36) [PYY(3-36)] that produces a sustained reduction in daily food intake and adiposity in diet-induced obese rats."( Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats.
Buescher, JL; Chelikani, PK; Haver, AC; Reidelberger, RD, 2008
)
0.35
" Our aim here was to identify a dosing strategy for intraperitoneal (IP) infusion of GLP-1 homologue exendin-4 alone and with PYY(3-36) that produces a sustained reduction in daily food intake and body weight in diet-induced obese (DIO) rats."( Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
Anders, KL; Apenteng, BA; Haver, AC; Reidelberger, RD; Steenson, SM, 2011
)
0.37
" Previous animal model studies have utilised a range of olanzapine dosages, however the dosage that better mimics the human scenario of olanzapine-induced weight gain is unclear."( Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.
Deng, C; Huang, XF; Weston-Green, K, 2011
)
0.37
" Sitagliptin increased active GLP-1, but caused a profound suppression of total PYY, GLP-1, and GIP when dosed alone or with GSK263."( Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ, 2014
)
0.4
"Peptide YY3-36 [PYY(3-36)] has shown efficacy in appetite suppression when dosed by injection modalities (intraperitoneal (IP)/subcutaneous)."( Inhaled PYY(3-36) dry-powder formulation for appetite suppression.
Boyden, T; Dobry, DE; Doyle-Eisele, M; Friesen, DT; Kuehl, PJ; Lyon, DK; McDonald, JD; Murri, BG; Vodak, DT, 2016
)
0.43
" In addition, mini-pigs were also dosed with PYY1-36-amide, PYY3-35, PYY3-34 and [N-methyl 34Q]-PYY3-36-amide in order to investigate the mechanisms by which PYY was metabolized."( Metabolism of peptide YY 3-36 in Göttingen mini-pig and rhesus monkey.
Jorgensen, R; Kofoed, J; Nielsen, FS; Olsen, J; Wulff, BS; Østergaard, S, 2016
)
0.43
" Study 1 compared the bioavailability and effects on circulating glucose and gut hormones (glucagon-like peptide-1, peptide YY) of Metformin DR dosed twice-daily to twice-daily immediate-release metformin (Metformin IR)."( Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
Baron, A; Burns, C; Buse, JB; DeFronzo, RA; Fineman, M; Kim, T; Skare, S, 2016
)
0.43
"Exercise-induced changes in appetite-regulating hormones may be intensity-dependent, however a clear dose-response relationship has not been established."( Total PYY and GLP-1 responses to submaximal continuous and supramaximal sprint interval cycling in men.
Copeland, JL; Hallworth, JR; Hazell, TJ; Islam, H, 2017
)
0.46
"c dosing with the combination of PYY(3-36) (200 μg/kg) and Ex4 (2."( PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.
Kjaergaard, M; Raun, K; Rehfeld, JF; Salinas, CBG; Secher, A; Wulff, BS, 2019
)
0.51
" Briefly, minks were fasted one day before experiment and given DAS by intraperitoneally and orally dosing on the experiment day."( Type A Trichothecene Diacetoxyscirpenol-Induced Emesis Corresponds to Secretion of Peptide YY and Serotonin in Mink.
Kuca, K; Nepovimova, E; Wu, Q; Wu, W, 2020
)
0.56
" To obtain long half-lives allowing for up to once-weekly dosing regimen, fatty acid acylation (lipidation) have been used to non-covalently associate the peptide to serum albumin thus serving as a circulating depot."( The effect of fatty diacid acylation of human PYY
Christoffersen, BØ; Jeppesen, CB; Jørgensen, R; Kofoed, J; Nielsen, FS; Olsen, J; Paulsson, JF; Raun, K; Schleiss, LG; Sensfuss, U; Spetzler, J; Wulff, BS; Ynddal, L; Zosel, F; Østergaard, S, 2021
)
0.62
"Exercise in young adults (18-25 yr) suppresses appetite in a dose-response relationship with exercise intensity."( Intense interval exercise induces lactate accumulation and a greater suppression of acylated ghrelin compared with submaximal exercise in middle-aged adults.
Bornath, DPD; Hazell, TJ; Jarosz, C; Kenno, KA; McCarthy, SF; Medeiros, PJ; Tucker, JAL, 2023
)
0.91
" While emesis induced by intraperitoneally dosed to DON in the mink has been related to plasma up-grading of 5-hydroxytryptamine (5-HT) and neurotransmitters peptide YY (PYY), the impact of oral dosing with DON or its four congeners on secretion of these chemical substances have not been established."( Emesis to trichothecene deoxynivalenol and its congeners correspond to secretion of peptide YY and 5-HT.
Guo, X; Kuca, K; Qin, Z; Wei, B; Wu, Q; Wu, W; Xiao, H; Xu, B, 2023
)
0.91
" Thus dosage pattern is critical for producing a sustained effect of PYY(3-36) on food intake and adiposity."( Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats.
Chelikani, PK; Haver, AC; Keire, DA; Reeve, JR; Reidelberger, RD, 2006
)
0.33
" In addition, a formulation containing PYY(3-36) and TJM peptide was dosed intranasally in rabbits, resulting in a dramatic increase in bioavailability."( Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.
Chen, SC; Costantino, HR; Cui, K; Eiting, K; Farber, K; Houston, ME; Johnson, PH; Leonard, AK; Li, CY; Morris, D; Quay, SC; Sileno, AP, 2006
)
0.33
" This dosing strategy produced a sustained reduction in daily caloric intake of 11-32% and prevented body weight gain (8 +/- 6 vs."( Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.
Chelikani, PK; Haver, AC; Reidelberger, RD, 2007
)
0.34
" A dose-dependent reduction in body weight in diet-induced obese (DIO) mice is seen following daily dosing for 14 days."( A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.
Buckholz, TM; Claus, TH; DeCarr, LB; Livingston, JN; Lumb, KJ; Mahle, CD; Mays, MR; Milardo, LF; Ortiz, AA, 2007
)
0.34
" Our aim here was to identify an intermittent dosing strategy for intraperitoneal infusion of peptide YY(3-36) [PYY(3-36)] that produces a sustained reduction in daily food intake and adiposity in diet-induced obese rats."( Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats.
Buescher, JL; Chelikani, PK; Haver, AC; Reidelberger, RD, 2008
)
0.35
" Our aim here was to identify a dosing strategy for intraperitoneal (IP) infusion of GLP-1 homologue exendin-4 alone and with PYY(3-36) that produces a sustained reduction in daily food intake and body weight in diet-induced obese (DIO) rats."( Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
Anders, KL; Apenteng, BA; Haver, AC; Reidelberger, RD; Steenson, SM, 2011
)
0.37
" Previous animal model studies have utilised a range of olanzapine dosages, however the dosage that better mimics the human scenario of olanzapine-induced weight gain is unclear."( Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.
Deng, C; Huang, XF; Weston-Green, K, 2011
)
0.37
"Peptide YY3-36 [PYY(3-36)] has shown efficacy in appetite suppression when dosed by injection modalities (intraperitoneal (IP)/subcutaneous)."( Inhaled PYY(3-36) dry-powder formulation for appetite suppression.
Boyden, T; Dobry, DE; Doyle-Eisele, M; Friesen, DT; Kuehl, PJ; Lyon, DK; McDonald, JD; Murri, BG; Vodak, DT, 2016
)
0.43
" In addition, mini-pigs were also dosed with PYY1-36-amide, PYY3-35, PYY3-34 and [N-methyl 34Q]-PYY3-36-amide in order to investigate the mechanisms by which PYY was metabolized."( Metabolism of peptide YY 3-36 in Göttingen mini-pig and rhesus monkey.
Jorgensen, R; Kofoed, J; Nielsen, FS; Olsen, J; Wulff, BS; Østergaard, S, 2016
)
0.43
"c dosing with the combination of PYY(3-36) (200 μg/kg) and Ex4 (2."( PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.
Kjaergaard, M; Raun, K; Rehfeld, JF; Salinas, CBG; Secher, A; Wulff, BS, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,260)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990173 (7.65)18.7374
1990's496 (21.95)18.2507
2000's586 (25.93)29.6817
2010's820 (36.28)24.3611
2020's185 (8.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials354 (15.15%)5.53%
Trials39 (15.00%)5.53%
Reviews252 (10.78%)6.00%
Reviews22 (8.46%)6.00%
Case Studies15 (0.64%)4.05%
Case Studies0 (0.00%)4.05%
Observational9 (0.39%)0.25%
Observational1 (0.38%)0.25%
Other1,707 (73.04%)84.16%
Other198 (76.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]